

Project Title	Funding	Strategic Plan Objective	Institution
1/3-Atomoxetine placebo and parent training in autism	\$272,700	Q4.S.F	University of Pittsburgh
1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$366,035	Q4.L.C	Indiana University-Purdue University Indianapolis
2/3-Atomoxetine placebo and parent training in autism	\$361,873	Q4.S.F	Ohio State University
2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$325,136	Q4.L.C	Seattle Children's Hospital
3/3-Atomoxetine placebo and parent training in autism	\$277,198	Q4.S.F	University of Rochester
3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD	\$391,103	Q4.L.C	University of California, Los Angeles
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$564,924	Q4.L.C	Yale University
ACE Center: The pharmacogenetics of treatment for insistence sameness in autism	\$382,540	Q4.L.A	University of Illinois at Chicago
ACE Center: Understanding repetitive behavior in autism	\$326,665	Q4.L.A	University of California, Los Angeles
ACE Network: Early pharmacotherapy guided by biomarkers in autism	\$1,000,000	Q4.S.F	Wayne State University
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$94,832	Q4.L.A	Stanford University
Autism Intervention Research Network on Physical Health (AIR-P network)	\$3,651,425	Q4.S.A	Massachusetts General Hospital
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)	\$619,865	Q4.S.F	Medical University of South Carolina
Building a selective inhibitory control tone in autism: An rTMS study	\$222,000	Q4.Other	University of Louisville
Clinical Trials Network	\$0	Q4.L.A	Autism Speaks (AS)
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,974	Q4.L.C	Indiana University
Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine	\$0	Q4.L.A	The Ohio State University
Pharmacotherapy of pervasive developmental disorders	\$184,587	Q4.L.C	Indiana University-Purdue University Indianapolis
Predictors of effects of propranolol on language & connectivity in autism	\$184,288	Q4.S.F	University of Missouri
Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Q4.L.A	Childrens Hospital Boston

Project Title	Funding	Strategic Plan Objective	Institution
Survey on treatment for children with autism with and without seizures	\$7,500	Q4.Other	Children's Learning Institute
Targeted pharmacologic interventions for autism	\$370,481	Q4.L.C	Indiana University-Purdue University Indianapolis
The effects of oxytocin on complex social cognition in autism spectrum disorders	\$285,221	Q4.L.A	Mount Sinai School of Medicine
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$127,500	Q4.S.A	Baylor College of Medicine
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$8,775	Q4.S.A	Baylor College of Medicine
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$770,674	Q4.L.A	National Institutes of Health

